/
Biological products, (no diagnostic substances) company · DE · FY ends Dec · -$8M FCF
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from -37.19% to -135.27%, capital efficiency is deteriorating. Negative free cash flow of -$6M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$6M
▼ -90.7% YoY
Op. Margin
—
ROIC
-135.27%
▼ -98.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$8M
▼ -34.2% YoY
Op. Cash Flow (TTM)
-$8M
▼ -34.2% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$6M
Continue Research